top of page
Executive Spotlights

COUR Pharmaceuticals Secures $105M in Series A Financing

Chicago, IL, January 30, 2024 (Globe Newswire) -- COUR Pharmaceuticals has secured approximately $105 million in financing, marking a significant milestone in its pursuit of innovative therapeutic solutions. A clinical-stage biotechnology company dedicated to advancing first-in-class, disease-modifying therapies aimed at inducing antigen-specific tolerance for immune-mediated diseases, Cour has successfully concluded its Series A investment round.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page